| Mrs Haley Dawn Kickland, DNP, FNP-BC | |
|
1101 E 7th St, Atlantic, IA 50022-1812 | |
| (712) 243-5790 | |
| (712) 243-3975 |
| Full Name | Mrs Haley Dawn Kickland |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 16 Years |
| Location | 1101 E 7th St, Atlantic, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043461080 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A-104483 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cass County Memorial Hospital | Atlantic, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Health Center Pc | 9931261641 | 2 |
News Archive
Michigan's state unemployment insurance agency has sent letters to 500,000 residents warning them that their benefits could expire starting in March if Congress fails to act on extending jobless benefits including a federal subsidy for COBRA health insurance, The Detroit News reports.
Researchers at Worcester Polytechnic Institute are developing a sensor the size of a Band-Aid that will measure a baby's blood oxygen levels, a vital indication of the lungs' effectiveness and whether the baby's tissue is receiving adequate oxygen supply.
Sudha Seshadri, M.D., founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases at UT Health San Antonio, is co-leader and senior author on research announced March 6 that identifies novel biomarkers of risk for future dementia.
A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
› Verified 3 days ago
| Entity Name | Midwest Health Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982856779 PECOS PAC ID: 9931261641 Enrollment ID: O20081215000179 |
News Archive
Michigan's state unemployment insurance agency has sent letters to 500,000 residents warning them that their benefits could expire starting in March if Congress fails to act on extending jobless benefits including a federal subsidy for COBRA health insurance, The Detroit News reports.
Researchers at Worcester Polytechnic Institute are developing a sensor the size of a Band-Aid that will measure a baby's blood oxygen levels, a vital indication of the lungs' effectiveness and whether the baby's tissue is receiving adequate oxygen supply.
Sudha Seshadri, M.D., founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases at UT Health San Antonio, is co-leader and senior author on research announced March 6 that identifies novel biomarkers of risk for future dementia.
A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Haley Dawn Kickland, DNP, FNP-BC 1101 E 7th St, Atlantic, IA 50022-1812 Ph: (712) 243-5790 | Mrs Haley Dawn Kickland, DNP, FNP-BC 1101 E 7th St, Atlantic, IA 50022-1812 Ph: (712) 243-5790 |
News Archive
Michigan's state unemployment insurance agency has sent letters to 500,000 residents warning them that their benefits could expire starting in March if Congress fails to act on extending jobless benefits including a federal subsidy for COBRA health insurance, The Detroit News reports.
Researchers at Worcester Polytechnic Institute are developing a sensor the size of a Band-Aid that will measure a baby's blood oxygen levels, a vital indication of the lungs' effectiveness and whether the baby's tissue is receiving adequate oxygen supply.
Sudha Seshadri, M.D., founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases at UT Health San Antonio, is co-leader and senior author on research announced March 6 that identifies novel biomarkers of risk for future dementia.
A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
› Verified 3 days ago
Tarrah L Holliday, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2307 Olive St, Atlantic, IA 50022 Phone: 712-243-2606 Fax: 712-243-2688 | |
Suzanne M Beitzel, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 | |
Mrs. Dianna Marie Prokupek, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1408 East 10th St, Atlantic, IA 50022 Phone: 712-243-2606 Fax: 712-243-2688 | |
Shannon Peterson, DNP, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 | |
Mrs. Shelli Dee Brown, ARNP, PMHNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2307 Olive St, Atlantic, IA 50022 Phone: 712-243-2606 Fax: 712-243-2688 | |
Mrs. Cynthia Y Wu, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-7510 |